Human liver cancer organoids: Biological applications, current challenges, and prospects in hepatoma therapy
Cancer Letters · 2023-02 · 555 · 216048
DOI: 10.1016/j.canlet.2022.216048 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2023-02. Verfasst von Lichan Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Inst Translat Med, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Guangz…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 164 Literaturangaben. Gefördert von: Medical Science and Technology Foundation of Guangdong Province, Basic and Applied Basic Research Foundation of Guangdong Province, Science and Technology Foundation of Shenzhen City.
Abstract (Originalsprache)
Liver cancer and disease are among the most socially challenging global health concerns. Although organ transplantation, surgical resection and anticancer drugs are the main methods for the treatment of liver cancer, there are still no proven cures owing to the lack of donor livers and tumor heterogeneity. Recently, advances in tumor organoid technology have attracted considerable attention as they can simulate the spatial constructs and pathophysiological characteristics of tumorigenesis and metastasis in a more realistic manner. Organoids may further contribute to the development of tailored therapies. Combining organoids with other emerging techniques, such as CRISPR-HOT, organ-on-a-chip, and 3D bioprinting, may further develop organoids and address their bottlenecks to create more practical models that generalize different tissue or organ interactions in tumor progression. In this review, we summarize the various methods in which liver organoids may be generated and describe their biological and clinical applications, present challenges, and prospects for their integration with emerging technologies. These rapidly developing liver organoids may become the focus of in vitro clinical model development and therapeutic research for liver diseases in the near future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Inst Translat Med, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangzhou, China. Electronic address: 98704565…
- Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China. Electronic address: sofea909@163.com.
- Department of Laboratory Medicine, Inst Translat Med, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangzhou, China. Electronic address: wanhood@…
- Department of Laboratory Medicine, Inst Translat Med, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangzhou, China. Electronic address: Xuyong_2…
- Department of Laboratory Medicine, Inst Translat Med, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Guangzhou Medical University, Guangzhou, China. Electronic address: zhouhong…
Förderung
- Medical Science and Technology Foundation of Guangdong Province
- Basic and Applied Basic Research Foundation of Guangdong Province
- Science and Technology Foundation of Shenzhen City
- National Natural Science Foundation of China
- Ministry of Education of the People's Republic of China
- Sun Yat-sen University
Zitieren
APA
Chen, L., Wei, X., Gu, D., Xu, Y., & Zhou, H. (2023). Human liver cancer organoids: Biological applications, current challenges, and prospects in hepatoma therapy. Cancer Letters, 555, 216048. https://doi.org/10.1016/j.canlet.2022.216048
Vancouver
Chen L, Wei X, Gu D, Xu Y, Zhou H. Human liver cancer organoids: Biological applications, current challenges, and prospects in hepatoma therapy. Cancer Letters. 2023;555:216048. doi:10.1016/j.canlet.2022.216048
BibTeX
@article{Chen2023,
author = {Chen, Lichan and Wei, Xiafei and Gu, Dayong and Xu, Yong and Zhou, Hongzhong},
title = {Human liver cancer organoids: Biological applications, current challenges, and prospects in hepatoma therapy},
journal = {Cancer Letters},
year = {2023},
volume = {555},
pages = {216048},
doi = {10.1016/j.canlet.2022.216048}
}
EUVIMED